Merus NV at Morgan Stanley Global Healthcare Conference Transcript
So I think we're going to get started with the next session. Thanks very much for being with us. I'm Matthew Harrison, an investment banking with Morgan Stanley. Really pleased to have Merus with us for the next session. Quickly, before we get started and you read the disclosure statement, please note that all important disclosures appear on the Morgan Stanley public website at morganstanley.com/research disclosures. So with that, really pleased to have Bill Lundberg, CEO at Merus, with us.
I thought -- obviously, you have a lot of assets, a significant pipeline with your bispecifics and trispecifics and multi-specifics. But I think, as we were just talking about, your asset in head and neck, probably is most interesting to me, so I thought we'd start there.
Questions & Answers
Maybe you could just talk to us a little bit about the landscape there as we think about your approach there. A couple of other drugs looking at EGFR and head-and-neck, so how should
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |